Q-omics provides the consensus-scored SMPD1 profile across patient tissues and cancer cell-line models. SMPD1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SMPD1 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, SMPD1 protein abundance shows 21,841 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, COAD, and LSCC as cancer lineages where SMPD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMPD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMPD1 survival associations across molecular data types. SMPD1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMPD1 RNA expression–survival associations across cancer types. High SMPD1 expression shows unfavorable associations in MESO, LUSC and LGG, but favorable associations in SCLC, PAAD and LUAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for SMPD1 RNA expression.
This table summarizes SMPD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SMPD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMPD1 shows lower tumor expression in COAD, KIRC, THCA, LUAD, BLCA and LUSC. The COAD box plot shows higher SMPD1 RNA expression in normal versus tumor tissue (log2 FC = −1.644, t-test p < 0.001).
This table shows molecular features associated with SMPD1 in patient tissues and cancer cell lines. In patient samples, SMPD1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SMPD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and CNS.
